Cancer cell death-inducing radiotherapy: Impact on local tumour control, tumour cell proliferation and induction of systemic anti-tumour immunity

Advances in Experimental Medicine and Biology

Volumn 930, Issue , 2016, Pages 151-172

  Frey, Benjamin ^a   Derer, Anja ^a   Scheithauer, Heike ^b   Wunderlich, Roland ^c   Fietkau, Rainer ^a   Gaipl, Udo SOR ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Apoptosis; Autophagy; Danger signals; DNA damage; Immunogenic cell death; Immunotherapy; Necrosis; Radiotherapy; Senescence associated secretory phenotype

Indexed keywords

DNA; ALARMIN; HIGH MOBILITY GROUP B1 PROTEIN; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL DEATH; CELL PROLIFERATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA DAMAGE; HUMAN; IMMUNOGENICITY; IMMUNOSENESCENCE; MITOSIS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SENESCENCE ASSOCIATED SECRETORY PHENOTYPE; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; CANCER STEM CELL; CELL AGING; CELL DIVISION; DNA REPAIR; IMMUNE SYSTEM; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PATHOLOGY; PHYSIOLOGY; RADIATION RESPONSE; RADIATION TOLERANCE;

ALARMINS; ANIMALS; AUTOPHAGY; CELL AGING; CELL DEATH; CELL DIVISION; DNA DAMAGE; DNA REPAIR; DNA, NEOPLASM; HMGB1 PROTEIN; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; NEOPLASM PROTEINS; NEOPLASMS; NEOPLASTIC STEM CELLS; RADIATION TOLERANCE;

EID: 84984919506     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-39406-0_7     Document Type: Article

References (133)

1. Lederman M. The early history of radiotherapy: 1895-1939. Int J Radiat Oncol Biol Phys. 1981;7:639-48.
2. Goodman LS, Wintrobe MM, Dameshek W, et al. Landmark article Sept. 21, 1946: nitrogen mustard therapy. Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(betachloroethyl) amine hydrochloride for Hodgkin’s disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. By Louis S. Goodman, Maxwell M. Wintrobe, William Dameshek, Morton J. Goodman, Alfred Gilman and Margaret T. McLennan. JAMA. 1984;251:2255-61.
3. Kalbasi A, June CH, Haas N, et al. Radiation and immunotherapy: a synergistic combination. J Clin Invest. 2013;123:2756-63.
4. Aziz K, Nowsheen S, Pantelias G, et al. Targeting DNA damage and repair: embracing the pharmacological era for successful cancer therapy. Pharmacol Ther. 2012;133:334-50.
5. Ward JF. DNA damage produced by ionizing radiation in mammalian cells: identities, mechanisms of formation, and reparability. Prog Nucleic Acid Res Mol Biol. 1988;35:95-125.
6. Iliakis G. Backup pathways of NHEJ in cells of higher eukaryotes: cell cycle dependence. Radiother Oncol. 2009;92:310-5.
7. Bernier J, Hall EJ, Giaccia A. Radiation oncology: a century of achievements. Nat Rev Cancer. 2004;4:737-47.
8. Pajonk F, Vlashi E, McBride WH. Radiation resistance of cancer stem cells: the 4 R’s of radiobiology revisited. Stem Cells. 2010;28:639-48.
9. Helbig L, Koi L, Bruchner K, et al. Hypoxia-inducible factor pathway inhibition resolves tumor hypoxia and improves local tumor control after single-dose irradiation. Int J Radiat Oncol Biol Phys. 2014;88:159-66.
10. Murata T, Akagi K, Kimura H, et al. Analysis of cell kinetics after irradiation by flow cytometry:proliferative ability of G2-blocked cells after cell sorting. Oncol Rep. 1998;5:385-8.
11. Maier P, Wenz F, Herskind C. Radioprotection of normal tissue cells. Strahlenther Onkol. 2014;190:745-52.
12. Travis EL, Parkins CS, Down JD, et al. Repair in mouse lung between multiple small doses of X rays. Radiat Res. 1983;94:326-39.
13. Williams MV, Denekamp J, Fowler JF. A review of alpha/beta ratios for experimental tumors:implications for clinical studies of altered fractionation. Int J Radiat Oncol Biol Phys. 1985;11:87-96.
14. Qi XS, White J, Li XA. Is alpha/beta for breast cancer really low? Radiother Oncol. 2011;100:282-8.
15. Durante M, Reppingen N, Held KD. Immunologically augmented cancer treatment using modern radiotherapy. Trends Mol Med. 2013;19:565-82.
16. Orth M, Lauber K, Niyazi M, et al. Current concepts in clinical radiation oncology. Radiat Environ Biophys. 2014;53:1-29.
17. Amornwichet N, Oike T, Shibata A, et al. Carbon-ion beam irradiation kills X-ray-resistant p53-null cancer cells by inducing mitotic catastrophe. PLoS One. 2014;9, e115121.
18. Fragkos M, Beard P. Mitotic catastrophe occurs in the absence of apoptosis in p53-null cells with a defective G1 checkpoint. PLoS One. 2011;6, e22946.
19. Castedo M, Perfettini JL, Roumier T, et al. Cell death by mitotic catastrophe: a molecular definition. Oncogene. 2004;23:2825-37.
20. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res. 1965;37:614-36.
21. Kurz DJ, Decary S, Hong Y, et al. Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J Cell Sci. 2000;113(Pt 20):3613-22.
22. Jones KR, Elmore LW, Jackson-Cook C, et al. p53-Dependent accelerated senescence induced by ionizing radiation in breast tumour cells. Int J Radiat Biol. 2005;81:445-58.
23. Kotter B, Frey B, Winderl M, et al. The in vitro immunogenic potential of caspase-3 profi-cient breast cancer cells with basal low immunogenicity is increased by hypofractionated irradiation. Radiat Oncol. 2015: 10. http197
24. Kroemer G, Galluzzi L, Vandenabeele P, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009;16:3-11.
25. Shelton DN, Chang E, Whittier PS, et al. Microarray analysis of replicative senescence. Curr Biol. 1999;9:939-45.
26. Coppe JP, Patil CK, Rodier F, et al. Senescence-associated secretory phenotypes reveal cell- nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008;6:2853-68.
27. Acosta JC, O’Loghlen A, Banito A, et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell. 2008;133:1006-18.
28. Kuilman T, Michaloglou C, Vredeveld LC, et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell. 2008;133:1019-31.
29. Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. J Pathol. 2010;221:3-12.
30. Klionsky DJ, Abdalla FC, Abeliovich H, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012;8:445-544.
31. Dalby KN, Tekedereli I, Lopez-Berestein G, et al. Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy. 2010;6:322-9.
32. Gewirtz DA. The four faces of autophagy: implications for cancer therapy. Cancer Res. 2014;74:647-51.
33. Shimizu S, Kanaseki T, Mizushima N, et al. Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol. 2004;6:1221-8.
34. Yang Y, Yang Y, Yang X, et al. Autophagy and its function in radiosensitivity. Tumour Biol. 2015;36:4079-87.
35. Liang XH, Jackson S, Seaman M, et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature. 1999;402:672-6.
36. Zhang D, Tang B, Xie X, et al. The interplay between DNA repair and autophagy in cancer therapy. Cancer Biol Ther. 2015;16:1005-13.
37. SenGupta T, Torgersen ML, Kassahun H, et al. Base excision repair AP endonucleases and mismatch repair act together to induce checkpoint-mediated autophagy. Nat Commun. 2013: 4. http2674
38. Figueiredo N, Chora A, Raquel H, et al. Anthracyclines induce DNA damage responsemediated protection against severe sepsis. Immunity. 2013;39:874-84.
39. Medzhitov R. Septic shock: on the importance of being tolerant. Immunity. 2013;39:799-800.
40. Lin W, Yuan N, Wang Z, et al. Autophagy confers DNA damage repair pathways to protect the hematopoietic system from nuclear radiation injury. Sci Rep. 2015: 5. http12362
41. Cottone L, Capobianco A, Gualteroni C, et al. 5-Fluorouracil causes leukocytes attraction in the peritoneal cavity by activating autophagy and HMGB1 release in colon carcinoma cells. Int J Cancer. 2015;136:1381-9.
42. Klug F, Prakash H, Huber PE, et al. Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 2013;24:589-602.
43. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239-57.
44. Lauber K, Blumenthal SG, Waibel M, et al. Clearance of apoptotic cells: getting rid of the corpses. Mol Cell. 2004;14:277-87.
45. Voll RE, Herrmann M, Roth EA, et al. Immunosuppressive effects of apoptotic cells. Nature. 1997;390:350-1.
46. Lauber K, Munoz LE, Berens C, et al. Apoptosis induction and tumor cell repopulation: the yin and yang of radiotherapy. Radiat Oncol. 2011: 6. http176
47. Belka C, Heinrich V, Marini P, et al. Ionizing radiation and the activation of caspase-8 in highly apoptosis-sensitive lymphoma cells. Int J Radiat Biol. 1999;75:1257-64.
48. Kerbel RS. Impact of multicellular resistance on the survival of solid tumors, including micrometastases. Invasion Metastasis. 1994;14:50-60.
49. Rafii A, Touboul C, Al Thani H, et al. Where cancer genomics should go next: a clinician’s perspective. Hum Mol Genet. 2014;23:R69-75.
50. Jiang M, Axe T, Holgate R, et al. p53 binds the nuclear matrix in normal cells: binding involves the proline-rich domain of p53 and increases following genotoxic stress. Oncogene. 2001;20:5449-58.
51. Sengupta S, Harris CC. p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol. 2005;6:44-55.
52. Baptiste N, Prives C. p53 in the cytoplasm: a question of overkill? Cell. 2004;116:487-9.
53. Sheikh MS, Burns TF, Huang Y, et al. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res. 1998;58:1593-8.
54. Yoon KW, Byun S, Kwon E, et al. Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53. Science. 2015: 349. http1261669
55. Wakatsuki M, Ohno T, Iwakawa M, et al. p73 protein expression correlates with radiationinduced apoptosis in the lack of p53 response to radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2008;70:1189-94.
56. Kroemer G, Galluzzi L, Kepp O, et al. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51-72.
57. de Bruyn M, Wiersma VR, Helfrich W, et al. The ever-expanding immunomodulatory role of calreticulin in cancer immunity. Front Oncol. 2015: 5. http35
58. Tesniere A, Schlemmer F, Boige V, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010;29:482-91.
59. Zitvogel L, Kepp O, Senovilla L, et al. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res. 2010;16:3100-4.
60. Frey B, Rubner Y, Wunderlich R, et al. Induction of abscopal anti-tumor immunity and immunogenic tumor cell death by ionizing irradiation-implications for cancer therapies. Curr Med Chem. 2012;19:1751-64.
61. Gaipl US, Sheriff A, Franz S, et al. Inefficient clearance of dying cells and autoreactivity. Curr Top Microbiol Immunol. 2006;305:161-76.
62. Kocher M, Wittig A, Piroth MD, et al. Stereotactic radiosurgery for treatment of brain metastases. A report of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlenther Onkol. 2014;190:521-32.
63. Krysko O, Love Aaes T, Bachert C, et al. Many faces of DAMPs in cancer therapy. Cell Death Dis. 2013;4, e631.
64. Holler N, Zaru R, Micheau O, et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol. 2000;1:489-95.
65. Degterev A, Hitomi J, Germscheid M, et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol. 2008;4:313-21.
66. Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation. Nature. 2015;517:311-20.
67. Fulda S. Therapeutic exploitation of necroptosis for cancer therapy. Semin Cell Dev Biol. 2014;35:51-6.
68. Mantel F, Frey B, Haslinger S, et al. Combination of ionising irradiation and hyperthermia activates programmed apoptotic and necrotic cell death pathways in human colorectal carcinoma cells. Strahlenther Onkol. 2010;186:587-99.
69. Werthmoller N, Frey B, Wunderlich R, et al. Modulation of radiochemoimmunotherapyinduced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces antitumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner. Cell Death Dis. 2015;6, e1761.
70. Kepp O, Senovilla L, Vitale I, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2014;3, e955691.
71. Stadler K, Frey B, Munoz LE, et al. Photopheresis with UV-A light and 8-methoxypsoralen leads to cell death and to release of blebs with anti-inflammatory phenotype in activated and non-activated lymphocytes. Biochem Biophys Res Commun. 2009;386:71-6.
72. Pineda JR, Daynac M, Chicheportiche A, et al. Vascular-derived TGF-beta increases in the stem cell niche and perturbs neurogenesis during aging and following irradiation in the adult mouse brain. EMBO Mol Med. 2013;5:548-62.
73. Xie Y, Bai O, Yuan J, et al. Tumor apoptotic bodies inhibit CTL responses and antitumor immunity via membrane-bound transforming growth factor-beta1 inducing CD8+ T-cell anergy and CD4+ Tr1 cell responses. Cancer Res. 2009;69:7756-66.
74. Derer A, Deloch L, Rubner Y, et al. Radio-immunotherapy-induced immunogenic cancer cells as basis for induction of systemic anti-tumor immune responses-pre-clinical evidence and ongoing clinical applications. Front Immunol. 2015;6:1-19.
75. Multhoff G, Pockley AG, Streffer C, et al. Dual role of heat shock proteins (HSPs) in antitumor immunity. Curr Mol Med. 2012;12:1174-82.
76. Galluzzi L, Senovilla L, Zitvogel L, et al. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov. 2012;11:215-33.
77. Fucikova J, Moserova I, Truxova I, et al. High hydrostatic pressure induces immunogenic cell death in human tumor cells. Int J Cancer. 2014;135:1165-77.
78. Kang TW, Yevsa T, Woller N, et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature. 2011;479:547-51.
79. Meng Y, Efimova EV, Hamzeh KW, et al. Radiation-inducible immunotherapy for cancer:senescent tumor cells as a cancer vaccine. Mol Ther. 2012;20:1046-55.
80. Lauber K, Ernst A, Orth M, et al. Dying cell clearance and its impact on the outcome of tumor radiotherapy. Front Oncol. 2012: 2. http116
81. Rovere P, Vallinoto C, Bondanza A, et al. Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J Immunol. 1998;161:4467-71.
82. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74.
83. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991-8.
84. Candeias SM, Gaipl US. The immune system in cancer prevention, development and therapy. Anticancer Agents Med Chem. 2015;16:101-7.
85. Frey B, Rubner Y, Kulzer L, et al. Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancer Immunol Immunother. 2014;63:29-36.
86. Hodge JW, Ardiani A, Farsaci B, et al. The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. Semin Oncol. 2012;39:323-39.
87. Vanpouille-Box C, Diamond JM, Pilones KA, et al. TGFbeta is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res. 2015;75:2232-42.
88. Demaria S, Ng B, Devitt ML, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004;58:862-70.
89. Mavragani IV, Laskaratou DA, Frey B, et al. Key mechanisms involved in ionizing radiationinduced systemic effects. A current review. Toxicol Res. 2016;5:12-33.
90. Prasanna A, Ahmed MM, Mohiuddin M, et al. Exploiting sensitization windows of opportunity in hyper and hypo-fractionated radiation therapy. J Thorac Dis. 2014;6:287-302.
91. Zeng J, See AP, Phallen J, et al. Anti-PD-1 blockade and stereotactic radiation produce longterm survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86:343-9.
92. Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009;15:5379-88.
93. Kulzer L, Rubner Y, Deloch L, et al. Norm- and hypo-fractionated radiotherapy is capable of activating human dendritic cells. J Immunotoxicol. 2014;11:328-36.
94. Burnette BC, Liang H, Lee Y, et al. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res. 2011;71:2488-96.
95. Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114:589-95.
96. Ganss R, Ryschich E, Klar E, et al. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 2002;62:1462-70.
97. Hatfield P, Merrick A, Harrington K, et al. Radiation-induced cell death and dendritic cells:potential for cancer immunotherapy? Clin Oncol (R Coll Radiol). 2005;17:1-11.
98. Barcellos-Hoff MH, Derynck R, Tsang ML, et al. Transforming growth factor-beta activation in irradiated murine mammary gland. J Clin Invest. 1994;93:892-9.
99. Shahabi V, Postow MA, Tuck D, et al. Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy. Am J Clin Oncol. 2015;38:90-7.
100. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 2013;19:5300-9.
101. Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889-94.
102. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415-21.
103. Persa E, Balogh A, Safrany G, et al. The effect of ionizing radiation on regulatory T cells in health and disease. Cancer Lett. 2015;368:252-61.
104. Bos PD, Plitas G, Rudra D, et al. Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. J Exp Med. 2013;210:2435-66.
105. Durakovic N, Bezak KB, Skarica M, et al. Host-derived Langerhans cells persist after MHC- matched allografting independent of donor T cells and critically influence the alloresponses mediated by donor lymphocyte infusions. J Immunol. 2006;177:4414-25.
106. Price JG, Idoyaga J, Salmon H, et al. CDKN1A regulates Langerhans cell survival and promotes Treg cell generation upon exposure to ionizing irradiation. Nat Immunol. 2015;16:1060-8.
107. Xu J, Escamilla J, Mok S, et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. 2013;73:2782-94.
108. Frey B, Gaipl US. Radio-immunotherapy: the focused beam expands. Lancet Oncol. 2015;16:742-3.
109. Zitvogel L, Kroemer G. Subversion of anticancer immunosurveillance by radiotherapy. Nat Immunol. 2015;16:1005-7.
110. Golden EB, Chhabra A, Chachoua A, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015;16:795-803.
111. Lauber K, Herrmann M. Tumor biology: with a little help from my dying friends. Curr Biol. 2015;25:R198-201.
112. Ford CA, Petrova S, Pound JD, et al. Oncogenic properties of apoptotic tumor cells in aggressive B cell lymphoma. Curr Biol. 2015;25:577-88.
113. Biswas SK, Allavena P, Mantovani A. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol. 2013;35:585-600.
114. Weber M, Moebius P, Buttner-Herold M, et al. Macrophage polarisation changes within the time between diagnostic biopsy and tumour resection in oral squamous cell carcinomas-an immunohistochemical study. Br J Cancer. 2015;113:510-9.
115. Revesz L. Effect of tumour cells killed by x-rays upon the growth of admixed viable cells. Nature. 1956;178:1391-2.
116. van den Brenk HA, Crowe MC, Stone MG. Reactions of the tumour bed to lethally irradiated tumour cells, and the Revesz effect. Br J Cancer. 1977;36:94-104.
117. Chaurio R, Janko C, Schorn C, et al. UVB-irradiated apoptotic cells induce accelerated growth of co-implanted viable tumor cells in immune competent mice. Autoimmunity. 2013;46:317-22.
118. Willems JJ, Arnold BP, Gregory CD. Sinister self-sacrifice: the contribution of apoptosis to malignancy. Front Immunol. 2014: 5. http299
119. Truman LA, Ford CA, Pasikowska M, et al. CX3CL1/fractalkine is released from apoptotic lymphocytes to stimulate macrophage chemotaxis. Blood. 2008;112:5026-36.
120. Tardaguila M, Mira E, Garcia-Cabezas MA, et al. CX3CL1 promotes breast cancer via transactivation of the EGF pathway. Cancer Res. 2013;73:4461-73.
121. Moschini I, Dell’Anna C, Losardo PL, et al. Radiotherapy of non-small-cell lung cancer in the era of EGFR gene mutations and EGF receptor tyrosine kinase inhibitors. Future Oncol. 2015;11:2329-42.
122. Huang Q, Li F, Liu X, et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med. 2011;17:860-6.
123. Hughes R, Qian BZ, Rowan C, et al. Perivascular M2 macrophages stimulate tumor relapse after chemotherapy. Cancer Res. 2015;75:3479-91.
124. Miles K, Clarke DJ, Lu W, et al. Dying and necrotic neutrophils are anti-inflammatory secondary to the release of alpha-defensins. J Immunol. 2009;183:2122-32.
125. Carretero R, Sektioglu IM, Garbi N, et al. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol. 2015;16:609-17.
126. Gregory CD, Pound JD. Cell death in the neighbourhood: direct microenvironmental effects of apoptosis in normal and neoplastic tissues. J Pathol. 2011;223:177-94.
127. Oishi N, Wang XW. Novel therapeutic strategies for targeting liver cancer stem cells. Int J Biol Sci. 2011;7:517-35.
128. Nicolay NH, Sommer E, Perez RL, et al. Mesenchymal stem cells are sensitive to treatment with kinase inhibitors and ionizing radiation. Strahlenther Onkol. 2014;190:1037-45.
129. Holliday EB, Ahmed AA, Yoo SK, et al. Does cancer literature reflect multidisciplinary practice? A systematic review of oncology studies in the medical literature over a 20-year period. Int J Radiat Oncol Biol Phys. 2015;92:721-31.
130. Kadhim M, Salomaa S, Wright E, et al. Non-targeted effects of ionising radiation-implications for low dose risk. Mutat Res. 2013;752:84-98.
131. Belka C, Ottinger H, Kreuzfelder E, et al. Impact of localized radiotherapy on blood immune cells counts and function in humans. Radiother Oncol. 1999;50:199-204.
132. Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol. 2015;1(9):1325-32.
133. Frey B, Hehlgans S, Rodel F, et al. Modulation of inflammation by low and high doses of ionizing radiation: implications for benign and malign diseases. Cancer Lett. 2015;368(2):230-7.